# A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

> **NCT01490866** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 70 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Bevacizumab
- **DRUG:** 5-Fluorouracil
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01490866
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490866, "A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01490866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*